生物试剂
>
生化试剂
>
分析化学
> L-抗坏血酸 文献数量：1
加入收藏 取消收藏

L-抗坏血酸 文献数量：1  分析标准品

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
熔点：190-194 °C
包装规格：100mg 1g in glass bottle
溶解性：溶于水
储备液保存：-80°C, 1 year -20°C, 6 months
体内实验：1、请依序添加每种溶剂： PBS Solubility: 100 mg/mL (567.79 mM); 澄清溶液; 超声助溶 (<60°C) ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
靶点：T-type calcium channel;Microbial Metabolite;
体外研究：L-Ascorbic acid 的抗癌作用由钠依赖性维生素 C 转运蛋白 2 (SVCT-2) 决定，它是 L-Ascorbic acid 的转运蛋白。L-Ascorbic acid (0.1 μM-2 mM) 根据 SVCT-2 表达和 L-ascorbic acid 摄取表现出抗癌作用。人结直肠癌细胞系对 L-Ascorbic acid 表现出不同的反应，这主要取决于 SVCT-2 的表达水平。
体内研究：L-Ascorbic acid/Tolbutamide 在正常 (60 mg/kg) 和糖尿病 (40 mg/kg) 条件下以剂量依赖性方式产生降血糖活性。在 L-Ascorbic acid 存在的情况下，与 Tolbutamide 匹配对照相比，Tolbuatmide (20 mg/kg) 起效早且维持时间更长。
细胞实验：Cell Viability Assay Cell Line: High SVCT-2 expressing cell lines Sw620, Sw480, LoVo, SNU-C4; Low SVCT-2 expressing cell lines HCT15, HCT116, DLD-1, CoLo-205 Concentration: 0, 0.1 μM, 1 μM, 10 μM, 0.1 mM, 0.5 mM, 1 mM, and 2 mM Incubation Time: 24 hours Result: Some high SVCT-2 expressing cancer cells demonstrated a dramatic cell-autonomous inhibitory effect of L-ascorbic acid. Low SVCT-2 expressing cell lines showed biphasic responses to L-ascorbic acid. Western Blot Analysis Cell Line: Sw620, Sw480, LoVo, SNU-C4, HCT15, HCT116, DLD-1, CoLo-205 cell lines Concentration: 1 mM Incubation Time: Result: The cell lines showed different levels of SVCT-2 expression in western blot analyses: Sw620, Sw480, and Lovo expressed high levels of SVCT-2 whereas HCT116, HCT15, and DLD-1 expressed low levels.
动物实验：Animal Model: Normal rats:Albino rats of either sex weighing between 125-175 g Dosage: Group I received L-ascorbic acid 60 mg/kg, Group II received Tolbutamide 20 mg/kg and Group III was given L-ascorbic acid (60 mg/kg) prior to the administration of tolbutamide 20 mg/kg Administration: Administered orally Result: L-ascorbic acid at the dose of 60 mg/kg produced 50.91% blood glucose reduction at 0.5 h and 20 mg/kg body weight of Tolbutamide produced 33% at 4 h as peak effects. In the presence of L-ascorbic acid (60 mg/kg), the action of Tolbutamide was early in onset and maintained for 6 h. Animal Model: Diabetic rats:Albino rats of either sex weighing between 125 to 175 g were fasted overnight before injection with Alloxan Dosage: Group I received L-ascorbic acid 40 mg/kg and Group II received Tolbutamide 20 mg/kg while Group III was given L-ascorbic acid 40 mg/kg prior to Tolbutamide administration (20 mg/kg). Administration: Oral administration Result: L-ascorbic acid (40 mg/kg alone) produced 42.53% blood glucose reduction at 1.5 h and Tolbutamide 20 mg/kg produced 45.09 at 4 h. Administration of L-ascorbic acid 40 mg/kg body weight prior to Tolbutamide produced antidiabetic activity at 0.5 h and was maintained for 6 h.
产品描述：抗氧化剂 掩蔽剂 还原剂
保存条件：室温
注意事项：1、为了您的安全和健康，请穿实验服并戴一次性手套操作。 2、以上信息仅做参考交流之用。

猜你喜欢